OncoMatch/Clinical Trials/NCT06574347

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Is NCT06574347 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Vebreltinib and Osimertinib for non-small-cell lung cancer.

Phase 2RecruitingAvistone Biotechnology Co., Ltd.NCT06574347Data as of May 2026

Treatment: Vebreltinib · Osimertinib · PLB1004 — Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR exon 19 deletion

EGFRm-positive (exon 19 deletion or L858R)

Required: EGFR L858R

EGFRm-positive (exon 19 deletion or L858R)

Required: MET overexpression (IHC 3+)

MET overexpression (IHC 3+)

Required: ALK mutation

There are mutations of ALK

Required: ROS1 mutation

There are mutations of ... ROS1

Disease stage

Required: Stage IIIB, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify